查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1625398

非酒精性脂肪性肝炎治疗市场、规模、占有率、趋势、行业分析报告（按药物、疾病阶段、分销管道和地区）- 市场预测，2025-2034 年

Non-alcoholic Steatohepatitis Treatment Market Size, Share, Trends, Industry Analysis Report: By Drug, Disease Stage, Distribution Channel, and Region - Market Forecast, 2025-2034
出版日期: | 出版商: Polaris Market Research | 英文 128 Pages | 商品交期: 最快1-2个工作天内

价格

根据 Polaris Market Research 的一项新研究，非酒精性脂肪性肝炎 (NASH) 治疗市场规模预计到 2034 年将达到 909.7 亿美元。该报告提供了有关当前市场动态的详细见解，并对未来市场的成长进行了分析。

非酒精性脂肪性肝炎 (NASH) 治疗市场的成长归因于肥胖、2 型糖尿病和代谢症候群等风险因素的日益流行，这些因素与 NASH 的发展密切相关。全球范围内 NASH 的盛行率日益上升，预计将为製药公司创造充足的市场机会。

由于针对 NASH 复杂病理生理学（包括肝炎、纤维化和胰岛素抗性）的研究力度不断加大以及创新疗法的出现，NASH 治疗市场预计将出现强劲的成长轨迹。由于全球NASH发生率的持续上升，尤其是北美、欧洲、亚太等地区，NASH治疗的市场规模呈现扩大趋势。

NASH 治疗市场的前景乐观，多种治疗方法正在通过临床试验并获得监管部门的批准，包括奥贝胆酸 (OCA)、索马鲁肽、lanifibranor 和维生素 E。医疗保健机会的扩大、对 NASH 认识的不断提高以及对肝病的日益关注，都促进了对 NASH 治疗的需求不断增长。此外，人口老化（特别是已开发国家的人口老化）推动了对创新治疗的需求。诊断和治疗方案的进步将推动大幅扩张，为医疗保健行业的利益相关者提供巨大的成长潜力和机会。

非酒精性脂肪性肝炎治疗市场报告重点

按药物分类，维生素 E 和吡格列酮部分将在 2024 年占据非酒精性脂肪性肝炎 (NASH) 治疗市场收入的最大占有率，因为它具有抑制肝炎和改善 NASH 患者胰岛素敏感性的功效。因为它已经成立了。

基于通路的零售和专业药房系统部门预计将在预测期内实现最高的复合年增长率，这得益于其易于获取以及能够为 NASH 的治疗提供专门的药物和患者支持。

由于肥胖和2 型糖尿病的盛行率高，以及医疗保健基础设施强大和肝病监测便利，预计到2024 年，北美将占据非酒精性脂肪性肝炎治疗市场占有率的主导地位。北美拥有大量投资来自

由于医疗保健支出的增加和人们对肝病管理的认识的不断提高，预计亚太市场在预测期内将出现显着增长。

全球市场的主要参与者是 Intercept Pharmaceuticals, Inc.；Galmed Pharmaceuticals Ltd；Inventiva；AbbVie Inc.；Galectin Therapeutics Inc.；Madrigal Pharmaceuticals Inc (Madrigal)；NGM Biopharmaceuticals, Inc.；Novo Nordisk A/S ；百时美施贵宝公司；以及吉利德科学公司。

目录

第 1 章简介

第 2 章执行摘要

第 3 章 研究方法

第 4 章全球非酒精性脂肪肝炎治疗市场洞察

  • 市场概况
  • 非酒精性脂肪性肝炎治疗市场动态
    • 推动因素和机遇
      • 老年人口增加
      • 2 型糖尿病发生率不断上升
    • 阻碍因素和课题
      • 医疗费用高昂
  • PESTEL 分析
  • 非酒精性脂肪性肝炎治疗市场趋势
  • 价值链分析
  • COVID-19 影响分析

第5章 全球非酒精性脂肪性肝炎治疗市场（依药物类型）

  • 主要发现
  • 简介
  • 维生素 E 和吡格列酮 奥贝胆酸 (OCA)
  • 拉尼菲布兰诺
  • 索马鲁肽
  • Resmetirom
  • 阿拉姆乔尔
  • 塞尼克里维罗克
  • 其他药物

第6章 全球非酒精性脂肪肝炎治疗市场（依疾病阶段）

  • 主要发现
  • 简介
  • NASH F0 期
  • NASH F1 期
  • NASH F2 期
  • NASH F3 期
  • NASH F4 期

第7章 全球非酒精性脂肪肝炎治疗市场（依通路）

  • 主要发现
  • 简介
  • 医院药房
  • 零售与专业药局
  • 其他药局

第 8 章全球非酒精性脂肪肝炎治疗市场（按地区）

  • 主要发现
  • 简介
    • 2020 年至 2034 年非酒精性脂肪性肝炎治疗市场各地区评估
  • 北美洲
    • 2020 年至 2034 年，北美各药物状况 北美：疾病阶段，2020 - 2034 年 2020 年至 2034 年北美按通路划分
    • 美国
    • 加拿大
  • 欧洲
      2020 年至 2034 年欧洲药物状况 欧洲：疾病阶段，2020 - 2034 年 2020 年至 2034 年欧洲按通路划分
    • 英国
    • 法国
    • 德国
    • 义大利
    • 西班牙
    • 荷兰
    • 俄罗斯
    • 其他欧洲国家
    亚太地区
      2020 年至 2034 年亚太地区药物类型 2020 年至 2034 年亚太地区疾病分期 2020 年至 2034 年亚太地区通路分布
    • 中国
    • 印度
    • 马来西亚
    • 日本
    • 印尼
    • 韩国
    • 澳大利亚
    • 其他亚太地区
  • 中东和非洲
      中东和非洲：按药物分类，2020 年至 2034 年 中东和非洲：疾病阶段，2020 年至 2034 年 2020 年至 2034 年中东和非洲按分销管道划分
    • 沙乌地阿拉伯
    • 阿拉伯联合大公国
    • 以色列
    • 南非
    • 其他中东和非洲地区
  • 拉丁美洲
    • 拉丁美洲，依药物分类，2020 年至 2034 年
    • 2020 年至 2034 年拉丁美洲各疾病阶段状况 2020 年至 2034 年拉丁美洲按通路划分
    • 墨西哥
    • 巴西
    • 阿根廷
    • 其他拉丁美洲国家

第 9 章 竞争格局

  • 扩张与收购分析
    • 放大
    • 收购
  • 伙伴关係/协作/协定/揭露

第10章 公司简介

  • Intercept Pharmaceuticals, Inc.
  • Galmed Pharmaceuticals Ltd
  • Inventiva
  • AbbVie Inc.
  • Galectin Therapeutics Inc.
  • Madrigal Pharmaceuticals Inc.（Madrigal）
  • NGM Biopharmaceuticals, Inc.
  • Novo Nordisk A/S
  • The Bristol-Myers Squibb Company
  • Gilead Sciences, Inc.
Product Code: PM5283

The non-alcoholic steatohepatitis treatment market size is expected to reach USD 90.97 billion by 2034, according to a new study by Polaris Market Research. The report "Non-alcoholic Steatohepatitis Treatment Market Share, Size, Trends, Industry Analysis Report: By Drug, Disease Stage, Distribution Channel (Hospital Pharmacies, Retail and Specialty Pharmacies, and Other Pharmacies), and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa); Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The non-alcoholic steatohepatitis (NASH) treatment market growth is attributed to the rising prevalence of risk factors such as obesity, type 2 diabetes, and metabolic syndrome, strongly linked to the development of NASH. The rising prevalence of NASH across the world is expected to create ample market opportunities for pharmaceutical companies.

The NASH treatment market is expected to experience a robust growth trajectory, increasing research efforts and innovative therapies targeting the complex pathophysiology of NASH, including liver inflammation, fibrosis, and insulin resistance. The market size for NASH treatments is expanding, with the global incidence of NASH continuing to rise, particularly in regions such as North America, Europe, and Asia Pacific.

The non-alcoholic steatohepatitis treatment market outlook is optimistic, with a growing number of drugs, including Obeticholic Acid (OCA), Semaglutide, Lanifibranor, and Vitamin E, advancing through clinical trials and receiving regulatory approvals. The expansion of healthcare access, increased awareness about NASH, and the growing focus on liver diseases contribute to the rising demand for NASH treatments. Moreover, the aging population, especially in developed countries, accelerates the need for innovative therapies. Advancements in diagnostics and treatment options are set to drive significant expansion, offering considerable growth potential and opportunities for stakeholders within the healthcare industry.

Non-alcoholic Steatohepatitis Treatment Market Report Highlights

In terms of drug, in 2024, the vitamin E and pioglitazone segment accounted for the largest share of the non-alcoholic steatohepatitis (NASH) treatment market revenue due to its well-established efficacy in reducing liver inflammation and improving insulin sensitivity in NASH patients.

The retail and specialty pharmacies systems segment, based on distribution channel, is expected to witness the highest CAGR during the forecast period due to its accessibility and ability to provide specialized medications and patient support for NASH treatment.

In 2024, North America dominated the non-alcoholic steatohepatitis treatment market share due to the high prevalence of obesity and type 2 diabetes, coupled with strong healthcare infrastructure and substantial investment in liver disease research.

The Asia Pacific market is expected to witness significant growth during the forecast period due to increasing healthcare expenditure and greater awareness of liver disease management.

A few global key market players are Intercept Pharmaceuticals, Inc.; Galmed Pharmaceuticals Ltd; Inventiva; AbbVie Inc.; Galectin Therapeutics Inc.; Madrigal Pharmaceuticals Inc (Madrigal); NGM Biopharmaceuticals, Inc.; Novo Nordisk A/S; The Bristol-Myers Squibb Company; and Gilead Sciences, Inc.

Polaris Market Research has segmented the non-alcoholic steatohepatitis treatment market report on the basis of drug, disease stage, distribution channel, and region:

By Drug Outlook (Revenue, USD Billion; 2020-2034)

  • Vitamin E and Pioglitazone
  • Obeticholic Acid (OCA)
  • Lanifibranor
  • Semaglutide
  • Resmetirom
  • Aramchol
  • Cenicriviroc
  • Other Drugs

By Disease Stage Outlook (Revenue, USD Billion; 2020-2034)

  • NASH Stage F0
  • NASH Stage F1
  • NASH Stage F2
  • NASH Stage F3
  • NASH Stage F4

By Distribution Channel Outlook (Revenue, USD Billion; 2020-2034)

  • Hospital Pharmacies
  • Retail and Specialty Pharmacies
  • Other Pharmacies

By Regional Outlook (Revenue, USD Billion; 2020-2034)

  • North America
  • US
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Malaysia
  • Australia
  • Rest of Asia Pacific
  • Latin America
  • Argentina
  • Brazil
  • Mexico
  • Rest of Latin America
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa
  • Rest of Middle East & Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Non-alcoholic Steatohepatitis Treatment Market Insights

  • 4.1. Non-alcoholic Steatohepatitis Treatment Market - Market Snapshot
  • 4.2. Non-alcoholic Steatohepatitis Treatment Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Rising Aging Population
      • 4.2.1.2. Rising Incidence of Type 2 Diabetes
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. High Treatment Costs
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTEL Analysis
  • 4.5. Non-alcoholic Steatohepatitis Treatment Market Trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Non-alcoholic Steatohepatitis Treatment Market, by Drug

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)
  • 5.3. Vitamin E and Pioglitazone
    • 5.3.1. Global Non-alcoholic Steatohepatitis Treatment Market, by Vitamin E and Pioglitazone, by Region, 2020-2034 (USD Billion)
  • 5.4. Obeticholic Acid (OCA)
    • 5.4.1. Global Non-alcoholic Steatohepatitis Treatment Market, by Obeticholic Acid (OCA), by Region, 2020-2034 (USD Billion)
  • 5.5. Lanifibranor
    • 5.5.1. Global Non-alcoholic Steatohepatitis Treatment Market, by Lanifibranor, by Region, 2020-2034 (USD Billion)
  • 5.6. Semaglutide
    • 5.6.1. Global Non-alcoholic Steatohepatitis Treatment Market, by Semaglutide, by Region, 2020-2034 (USD Billion)
  • 5.7. Resmetirom
    • 5.7.1. Global Non-alcoholic Steatohepatitis Treatment Market, by Resmetirom, by Region, 2020-2034 (USD Billion)
  • 5.8. Aramchol
    • 5.8.1. Global Non-alcoholic Steatohepatitis Treatment Market, by Aramchol, by Region, 2020-2034 (USD Billion)
  • 5.9. Cenicriviroc
    • 5.9.1. Global Non-alcoholic Steatohepatitis Treatment Market, by Cenicriviroc, by Region, 2020-2034 (USD Billion)
  • 5.10. Other Drugs
    • 5.10.1. Global Non-alcoholic Steatohepatitis Treatment Market, by Other Drugs, by Region, 2020-2034 (USD Billion)

6. Global Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)
  • 6.3. NASH Stage F0
    • 6.3.1. Global Non-alcoholic Steatohepatitis Treatment Market, by NASH Stage F0, by Region, 2020-2034 (USD Billion)
  • 6.4. NASH Stage F1
    • 6.4.1. Global Non-alcoholic Steatohepatitis Treatment Market, by NASH Stage F1, by Region, 2020-2034 (USD Billion)
  • 6.5. NASH Stage F2
    • 6.5.1. Global Non-alcoholic Steatohepatitis Treatment Market, by NASH Stage F2, by Region, 2020-2034 (USD Billion)
  • 6.6. NASH Stage F3
    • 6.6.1. Global Non-alcoholic Steatohepatitis Treatment Market, by NASH Stage F3, by Region, 2020-2034 (USD Billion)
  • 6.7. NASH Stage F4
    • 6.7.1. Global Non-alcoholic Steatohepatitis Treatment Market, by NASH Stage F4, by Region, 2020-2034 (USD Billion)

7. Global Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Global Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • 7.3. Hospital Pharmacies
    • 7.3.1. Global Non-alcoholic Steatohepatitis Treatment Market, by Hospital Pharmacies, by Region, 2020-2034 (USD Billion)
  • 7.4. Retail and Specialty Pharmacies
    • 7.4.1. Global Non-alcoholic Steatohepatitis Treatment Market, by Retail and Specialty Pharmacies, by Region, 2020-2034 (USD Billion)
  • 7.5. Other Pharmacies
    • 7.5.1. Global Non-alcoholic Steatohepatitis Treatment Market, by Other Pharmacies, by Region, 2020-2034 (USD Billion)

8. Global Non-alcoholic Steatohepatitis Treatment Market, by Geography

  • 8.1. Key Findings
  • 8.2. Introduction
    • 8.2.1. Non-alcoholic Steatohepatitis Treatment Market Assessment, By Geography, 2020-2034 (USD Billion)
  • 8.3. Non-alcoholic Steatohepatitis Treatment Market - North America
    • 8.3.1. North America: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)
    • 8.3.2. North America: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)
    • 8.3.3. North America: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.3.4. Non-alcoholic Steatohepatitis Treatment Market - U.S.
      • 8.3.4.1. U.S.: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)
      • 8.3.4.2. U.S.: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)
      • 8.3.4.3. U.S.: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.3.5. Non-alcoholic Steatohepatitis Treatment Market - Canada
      • 8.3.5.1. Canada: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)
      • 8.3.5.2. Canada: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)
      • 8.3.5.3. Canada: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • 8.4. Non-alcoholic Steatohepatitis Treatment Market - Europe
    • 8.4.1. Europe: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)
    • 8.4.2. Europe: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)
    • 8.4.3. Europe: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.4.4. Non-alcoholic Steatohepatitis Treatment Market - UK
      • 8.4.4.1. UK: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)
      • 8.4.4.2. UK: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)
      • 8.4.4.3. UK: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.4.5. Non-alcoholic Steatohepatitis Treatment Market - France
      • 8.4.5.1. France: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)
      • 8.4.5.2. France: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)
      • 8.4.5.3. France: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.4.6. Non-alcoholic Steatohepatitis Treatment Market - Germany
      • 8.4.6.1. Germany: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)
      • 8.4.6.2. Germany: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)
      • 8.4.6.3. Germany: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.4.7. Non-alcoholic Steatohepatitis Treatment Market - Italy
      • 8.4.7.1. Italy: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)
      • 8.4.7.2. Italy: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)
      • 8.4.7.3. Italy: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.4.8. Non-alcoholic Steatohepatitis Treatment Market - Spain
      • 8.4.8.1. Spain: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)
      • 8.4.8.2. Spain: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)
      • 8.4.8.3. Spain: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.4.9. Non-alcoholic Steatohepatitis Treatment Market - Netherlands
      • 8.4.9.1. Netherlands: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)
      • 8.4.9.2. Netherlands: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)
      • 8.4.9.3. Netherlands: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.4.10. Non-alcoholic Steatohepatitis Treatment Market - Russia
      • 8.4.10.1. Russia: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)
      • 8.4.10.2. Russia: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)
      • 8.4.10.3. Russia: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.4.11. Non-alcoholic Steatohepatitis Treatment Market - Rest of Europe
      • 8.4.11.1. Rest of Europe: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)
      • 8.4.11.2. Rest of Europe: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)
      • 8.4.11.3. Rest of Europe: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • 8.5. Non-alcoholic Steatohepatitis Treatment Market - Asia Pacific
    • 8.5.1. Asia Pacific: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)
    • 8.5.2. Asia Pacific: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)
    • 8.5.3. Asia Pacific: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.5.4. Non-alcoholic Steatohepatitis Treatment Market - China
      • 8.5.4.1. China: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)
      • 8.5.4.2. China: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)
      • 8.5.4.3. China: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.5.5. Non-alcoholic Steatohepatitis Treatment Market - India
      • 8.5.5.1. India: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)
      • 8.5.5.2. India: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)
      • 8.5.5.3. India: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.5.6. Non-alcoholic Steatohepatitis Treatment Market - Malaysia
      • 8.5.6.1. Malaysia: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)
      • 8.5.6.2. Malaysia: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)
      • 8.5.6.3. Malaysia: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.5.7. Non-alcoholic Steatohepatitis Treatment Market - Japan
      • 8.5.7.1. Japan: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)
      • 8.5.7.2. Japan: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)
      • 8.5.7.3. Japan: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.5.8. Non-alcoholic Steatohepatitis Treatment Market - Indonesia
      • 8.5.8.1. Indonesia: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)
      • 8.5.8.2. Indonesia: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)
      • 8.5.8.3. Indonesia: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.5.9. Non-alcoholic Steatohepatitis Treatment Market - South Korea
      • 8.5.9.1. South Korea: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)
      • 8.5.9.2. South Korea: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)
      • 8.5.9.3. South Korea: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.5.10. Non-alcoholic Steatohepatitis Treatment Market - Australia
      • 8.5.10.1. Australia: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)
      • 8.5.10.2. Australia: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)
      • 8.5.10.3. Australia: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.5.11. Non-alcoholic Steatohepatitis Treatment Market - Rest of Asia Pacific
      • 8.5.11.1. Rest of Asia Pacific: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)
      • 8.5.11.2. Rest of Asia Pacific: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)
      • 8.5.11.3. Rest of Asia Pacific: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • 8.6. Non-alcoholic Steatohepatitis Treatment Market - Middle East & Africa
    • 8.6.1. Middle East & Africa: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)
    • 8.6.2. Middle East & Africa: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)
    • 8.6.3. Middle East & Africa: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.6.4. Non-alcoholic Steatohepatitis Treatment Market - Saudi Arabia
      • 8.6.4.1. Saudi Arabia: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)
      • 8.6.4.2. Saudi Arabia: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)
      • 8.6.4.3. Saudi Arabia: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.6.5. Non-alcoholic Steatohepatitis Treatment Market - UAE
      • 8.6.5.1. UAE: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)
      • 8.6.5.2. UAE: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)
      • 8.6.5.3. UAE: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.6.6. Non-alcoholic Steatohepatitis Treatment Market - Israel
      • 8.6.6.1. Israel: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)
      • 8.6.6.2. Israel: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)
      • 8.6.6.3. Israel: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.6.7. Non-alcoholic Steatohepatitis Treatment Market - South Africa
      • 8.6.7.1. South Africa: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)
      • 8.6.7.2. South Africa: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)
      • 8.6.7.3. South Africa: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.6.8. Non-alcoholic Steatohepatitis Treatment Market - Rest of Middle East & Africa
      • 8.6.8.1. Rest of Middle East & Africa: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)
      • 8.6.8.2. Rest of Middle East & Africa: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)
      • 8.6.8.3. Rest of Middle East & Africa: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • 8.7. Non-alcoholic Steatohepatitis Treatment Market - Latin America
    • 8.7.1. Latin America: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)
    • 8.7.2. Latin America: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)
    • 8.7.3. Latin America: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.7.4. Non-alcoholic Steatohepatitis Treatment Market - Mexico
      • 8.7.4.1. Mexico: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)
      • 8.7.4.2. Mexico: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)
      • 8.7.4.3. Mexico: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.7.5. Non-alcoholic Steatohepatitis Treatment Market - Brazil
      • 8.7.5.1. Brazil: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)
      • 8.7.5.2. Brazil: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)
      • 8.7.5.3. Brazil: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.7.6. Non-alcoholic Steatohepatitis Treatment Market - Argentina
      • 8.7.6.1. Argentina: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)
      • 8.7.6.2. Argentina: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)
      • 8.7.6.3. Argentina: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.7.7. Non-alcoholic Steatohepatitis Treatment Market - Rest of Latin America
      • 8.7.7.1. Rest of Latin America: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)
      • 8.7.7.2. Rest of Latin America: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)
      • 8.7.7.3. Rest of Latin America: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)

9. Competitive Landscape

  • 9.1. Expansion and Acquisition Analysis
    • 9.1.1. Expansion
    • 9.1.2. Acquisitions
  • 9.2. Partnerships/Collaborations/Agreements/Exhibitions

10. Company Profiles

  • 10.1. Intercept Pharmaceuticals, Inc.
    • 10.1.1. Company Overview
    • 10.1.2. Financial Performance
    • 10.1.3. Product Benchmarking
    • 10.1.4. Recent Development
  • 10.2. Galmed Pharmaceuticals Ltd
    • 10.2.1. Company Overview
    • 10.2.2. Financial Performance
    • 10.2.3. Product Benchmarking
    • 10.2.4. Recent Development
  • 10.3. Inventiva
    • 10.3.1. Company Overview
    • 10.3.2. Financial Performance
    • 10.3.3. Product Benchmarking
    • 10.3.4. Recent Development
  • 10.4. AbbVie Inc.
    • 10.4.1. Company Overview
    • 10.4.2. Financial Performance
    • 10.4.3. Product Benchmarking
    • 10.4.4. Recent Development
  • 10.5. Galectin Therapeutics Inc.
    • 10.5.1. Company Overview
    • 10.5.2. Financial Performance
    • 10.5.3. Product Benchmarking
    • 10.5.4. Recent Development
  • 10.6. Madrigal Pharmaceuticals Inc. (Madrigal)
    • 10.6.1. Company Overview
    • 10.6.2. Financial Performance
    • 10.6.3. Product Benchmarking
    • 10.6.4. Recent Development
  • 10.7. NGM Biopharmaceuticals, Inc.
    • 10.7.1. Company Overview
    • 10.7.2. Financial Performance
    • 10.7.3. Product Benchmarking
    • 10.7.4. Recent Development
  • 10.8. Novo Nordisk A/S
    • 10.8.1. Company Overview
    • 10.8.2. Financial Performance
    • 10.8.3. Product Benchmarking
    • 10.8.4. Recent Development
  • 10.9. The Bristol-Myers Squibb Company
    • 10.9.1. Company Overview
    • 10.9.2. Financial Performance
    • 10.9.3. Product Benchmarking
    • 10.9.4. Recent Development
  • 10.10. Gilead Sciences, Inc.
    • 10.10.1. Company Overview
    • 10.10.2. Financial Performance
    • 10.10.3. Product Benchmarking
    • 10.10.4. Recent Development

List of Tables:

Table 1 Global Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)

Table 2 Global Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)

Table 3 Global Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)

Table 4 North America: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)

Table 5 North America: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)

Table 6 North America: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)

Table 7 U.S.: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)

Table 8 U.S.: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)

Table 9 U.S.: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)

Table 10 Canada: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)

Table 11 Canada: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)

Table 12 Canada: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)

Table 13 Europe: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)

Table 14 Europe: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)

Table 15 Europe: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)

Table 16 UK: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)

Table 17 UK: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)

Table 18 UK: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)

Table 19 France: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)

Table 20 France: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)

Table 21 France: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)

Table 22 Germany: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)

Table 23 Germany: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)

Table 24 Germany: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)

Table 25 Italy: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)

Table 26 Italy: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)

Table 27 Italy: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)

Table 28 Spain: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)

Table 29 Spain: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)

Table 30 Spain: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)

Table 31 Netherlands: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)

Table 32 Netherlands: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)

Table 33 Netherlands: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)

Table 34 Russia: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)

Table 35 Russia: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)

Table 36 Russia: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)

Table 37 Rest of Europe: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)

Table 38 Rest of Europe: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)

Table 39 Rest of Europe: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)

Table 40 Asia Pacific: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)

Table 41 Asia Pacific: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)

Table 42 Asia Pacific: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)

Table 43 China: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)

Table 44 China: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)

Table 45 China: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)

Table 46 India: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)

Table 47 India: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)

Table 48 India: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)

Table 49 Malaysia: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)

Table 50 Malaysia: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)

Table 51 Malaysia: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)

Table 52 Japan: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)

Table 53 Japan: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)

Table 54 Japan: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)

Table 55 Indonesia: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)

Table 56 Indonesia: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)

Table 57 Indonesia: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)

Table 58 South Korea: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)

Table 59 South Korea: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)

Table 60 South Korea: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)

Table 61 Australia: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)

Table 62 Australia: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)

Table 63 Australia: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)

Table 64 Rest of Asia Pacific: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)

Table 65 Rest of Asia Pacific: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)

Table 66 Rest of Asia Pacific: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)

Table 67 Middle East & Africa: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)

Table 68 Middle East & Africa: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)

Table 69 Middle East & Africa: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)

Table 70 Saudi Arabia: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)

Table 71 Saudi Arabia: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)

Table 72 Saudi Arabia: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)

Table 73 UAE: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)

Table 74 UAE: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)

Table 75 UAE: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)

Table 76 Israel: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)

Table 77 Israel: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)

Table 78 Israel: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)

Table 79 South Africa: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)

Table 80 South Africa: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)

Table 81 South Africa: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)

Table 82 Rest of Middle East & Africa: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)

Table 83 Rest of Middle East & Africa: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)

Table 84 Rest of Middle East & Africa: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)

Table 85 Latin America: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)

Table 86 Latin America: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)

Table 87 Latin America: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)

Table 88 Mexico: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)

Table 89 Mexico: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)

Table 90 Mexico: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)

Table 91 Brazil: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)

Table 92 Brazil: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)

Table 93 Brazil: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)

Table 94 Argentina: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)

Table 95 Argentina: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)

Table 96 Argentina: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)

Table 97 Rest of Latin America: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)

Table 98 Rest of Latin America: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)

Table 99 Rest of Latin America: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)

List of Figures:

Figure 1. Global Non-alcoholic Steatohepatitis Treatment Market, 2020-2034 (USD Billion)

Figure 2. Integrated Ecosystem

Figure 3. Research Methodology: Top-Down & Bottom-Up Price

Figure 4. Market by Geography

Figure 5. Porter's Five Forces

Figure 6. Market by Drug

Figure 7. Global Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2024 & 2034 (USD Billion)

Figure 8. Market by Disease Stage

Figure 9. Global Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2024 & 2034 (USD Billion)

Figure 10. Market by Distribution Channel

Figure 11. Global Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2024 & 2034 (USD Billion)